Sontuzumab
Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer[1].
Product Specifications
CAS Number
[372075-37-1]
Product Name Alternative
AS1402; huHMFG-1
UNSPSC
12352203
Target
Mucin
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sontuzumab.html
Purity
99.66
Solubility
H2O
Smiles
[Sontuzumab]
Molecular Weight
(145.38 kDa)
References & Citations
[1]Pegram MD, et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11 (5) :R73.|[2]Snijdewint FG, et al. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer. 2001 Jul 1;93 (1) :97-106.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99591/Sontuzumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99591/Sontuzumab-SDS-MedChemExpress.pdf
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
